Currently, mGlu7 is recognized as a targeted receptor for the development of pharmaceuticals against CNS disorders, such as epilepsy [19,20], schizophrenia [21-23], and anxiety [10,24,25]. The gene discussed is GRM7; the disease is central nervous system disorder.